Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current and under investigation treatments in pancreatic cancer. The book presents information on how to combine current therapy with treatment under development and/or in clinical trials in order to improve survival. Chapters review new modalities to cure oncolytic viruses and Bi-specific T cell engager (BiTEs) as future clinical treatments, along with discussions on recent research using those modalities in combination therapy. The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about new therapies. Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research, and clinical trialsEncompasses knowledge on Bi-specific T cell engager (BiTEs), focusing on its function, development and use on pancreatic cancerBrings information on recently developed combination therapies that allow for a lower dose of treatment and hence less side effects INDICE: 1. Pancreatic cancer generalities, current surgical treatment, updates2. Current chemotherapy and immunotherapy in pancreatic cancer3. Generalities of Oncolytic virus and HF10 in pancreatic cancer4. Oncolytic Adenovirus use in pancreatic cancer5. BiTE cell generalities and its potential use for pancreatic cancer6. Precision oncology for pancreatic cancer7. Strategies with immune therapy8. Combination therapies of current/ new options to treat pancreatic cancer in future

• ISBN: 978-0-12-822914-9
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Páginas: 250
• Fecha Publicación: 01/01/2021
• Nº Volúmenes: 1
• Idioma: Inglés